Roivant Sciences (NASDAQ:ROIV) CEO Sells $6,990,000.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $34.95, for a total transaction of $6,990,000.00. Following the completion of the transaction, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at approximately $56,376,551.85. This represents a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Wednesday, June 24th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $33.16, for a total transaction of $6,632,000.00.
• On Friday, May 22nd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $30.27, for a total transaction of $6,054,000.00.

Roivant Sciences Trading Down 2.9%

ROIV traded down $0.97 on Wednesday, reaching $32.87. The stock had a trading volume of 4,824,003 shares, compared to its average volume of 4,385,496. The business’s 50-day moving average price is $32.48 and its two-hundred day moving average price is $28.93. The company has a market cap of $23.64 billion, a P/E ratio of -54.78 and a beta of 1.11. Roivant Sciences Ltd. has a 12-month low of $10.90 and a 12-month high of $37.00.

Analysts Set New Price Targets

Several equities analysts recently weighed in on ROIV shares. HC Wainwright restated a “buy” rating and issued a $34.00 price target on shares of Roivant Sciences in a research note on Thursday, May 21st. Weiss Ratings lowered Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Leerink Partners set a $42.00 target price on Roivant Sciences in a research note on Thursday, May 21st. Finally, Citigroup upped their target price on Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.59.

Institutional Trading of Roivant Sciences

Institutional investors have recently made changes to their positions in the company. SBI Securities Co. Ltd. raised its stake in Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after purchasing an additional 1,166 shares during the last quarter. Allworth Financial LP boosted its stake in Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in shares of Roivant Sciences during the fourth quarter worth $47,000. Parallel Advisors LLC grew its holdings in shares of Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after buying an additional 520 shares in the last quarter. Finally, CIBC Private Wealth Group LLC raised its position in shares of Roivant Sciences by 7,614.3% in the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock valued at $59,000 after buying an additional 2,665 shares during the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.